Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob George

Showing results (751-760 of 849) with videos related to

Pageof 85
Sort By:
Hepatology Communications|May 16, 2018
Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infectionJacob George, Eduard Burnevich, I-Shyan Sheen, et al.
Trials|November 7, 2024
Implementing palliative care in hepatocellular carcinoma ambulatory clinics-study protocol for Accelerated translational research in PRImary liver CAncer (APRICA) randomised controlled palliative care trialCameron Gofton, Anna Di Bartolomeo, Rose Boutros, et al.
Cell Reports. Medicine|November 2, 2023
Identification and multicentric validation of soluble CDCP1 as a robust serological biomarker for risk stratification of NASH in obese ChineseXi Jia, Erfei Song, Yan Liu, et al.
Ebiomedicine|August 13, 2021
Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver diseaseMayada Metwally, Ali Bayoumi, Anis Khan, et al.
Gastroenterology|May 8, 2018
Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort StudyEduardo Vilar-Gomez, Luis Calzadilla-Bertot, Vincent Wai-Sun Wong, et al.
Digestive Diseases and Sciences|May 13, 2022
Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment CohortPaul J Clark, Patricia C Valery, Simone I Strasser, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 1, 2024
Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohortLiang-Jie Tang, Dan-Qin Sun, Sherlot Juan Song, et al.
Antiviral Research|October 13, 2024
Circulating capsid-antibody-complexes (CACs) drive intrahepatic complement deposition and inform subclinical liver inflammation in chronic hepatitis BYijie Tang, Mingzhu Xu, Cong Wang, et al.
Hepatology International|June 17, 2025
Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysisJing Chen, Dong Ji, Jidong Jia, et al.
Alimentary Pharmacology & Therapeutics|December 6, 2021
A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approachJeffrey V Lazarus, Henry E Mark, Massimo Colombo, et al.
Pageof 85

Showing results (751-760 of 849) with videos related to

Sort By:
Pageof 85
Hepatology Communications|May 16, 2018
Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infectionJacob George, Eduard Burnevich, I-Shyan Sheen, et al.
Trials|November 7, 2024
Implementing palliative care in hepatocellular carcinoma ambulatory clinics-study protocol for Accelerated translational research in PRImary liver CAncer (APRICA) randomised controlled palliative care trialCameron Gofton, Anna Di Bartolomeo, Rose Boutros, et al.
Cell Reports. Medicine|November 2, 2023
Identification and multicentric validation of soluble CDCP1 as a robust serological biomarker for risk stratification of NASH in obese ChineseXi Jia, Erfei Song, Yan Liu, et al.
Ebiomedicine|August 13, 2021
Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver diseaseMayada Metwally, Ali Bayoumi, Anis Khan, et al.
Gastroenterology|May 8, 2018
Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort StudyEduardo Vilar-Gomez, Luis Calzadilla-Bertot, Vincent Wai-Sun Wong, et al.
Digestive Diseases and Sciences|May 13, 2022
Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment CohortPaul J Clark, Patricia C Valery, Simone I Strasser, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 1, 2024
Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohortLiang-Jie Tang, Dan-Qin Sun, Sherlot Juan Song, et al.
Antiviral Research|October 13, 2024
Circulating capsid-antibody-complexes (CACs) drive intrahepatic complement deposition and inform subclinical liver inflammation in chronic hepatitis BYijie Tang, Mingzhu Xu, Cong Wang, et al.
Hepatology International|June 17, 2025
Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysisJing Chen, Dong Ji, Jidong Jia, et al.
Alimentary Pharmacology & Therapeutics|December 6, 2021
A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approachJeffrey V Lazarus, Henry E Mark, Massimo Colombo, et al.
Pageof 85